Compound VC
Compound VC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Compound VC.
Compound VC is a company.
Key people at Compound VC.
Compound VC is a thesis-driven, research-centric investment firm specializing in early-stage ventures across deeply technical and science-driven fields like AI/ML, robotics, biotech, healthcare, and crypto.[1][2][4][5] Its mission centers on accelerating founders' visions by providing hands-on support to solve complex technical challenges, communicate breakthroughs, and scale commercialization, leveraging a team of investors, researchers, and operators with domain expertise.[1][4][5] The firm's investment philosophy emphasizes "n-of-1" bets on underappreciated opportunities, informed by proprietary research and theses, with a broad portfolio including standout companies like Deepgram, Arbitrum, Dapper Labs, The Graph, and Compound protocol itself.[1][2][6] Compound has made 226 investments with check sizes typically ranging from $100K to $3M, focusing on pre-seed to Series A rounds, and plays a key role in the startup ecosystem by publishing public research that shapes industry thinking and aids founder development of novel mechanisms.[1][2][4][6]
Founded in 2016 by Michael Dempsey, Compound VC emerged in New York as a crypto-native firm, initially backing early protocols like The Graph, Compound, Arbitrum, Dapper Labs, Blockstack, Livepeer, and Kadena.[2][3][4] The firm has since evolved its focus to a broader "deep tech" mandate, expanding into AI/ML, robotics, biology, and healthcare while maintaining roots in technical, science-driven areas.[1][6] Key partners include General Partner David Hirsch and Venture Partners like Celeste Holz-Schietinger (ex-Impossible Foods biology expert), building a 17-person team of domain specialists who draw on prior operator experience to support portfolio growth.[1][3][5] Early traction came from crypto investments starting in 2016, with consistent participation in 7-12 rounds annually and notable exits peaking in 2019, solidifying its reputation for spotting high-potential science projects.[3]
Compound rides the surge in deep tech convergence, where AI/ML, robotics, biotech, and crypto intersect to tackle grand challenges like autonomous science, biosecurity, and decentralized infrastructure.[1][4][6] Timing aligns with post-2024 AI boom and crypto maturation, amplified by market forces like venturification of research (creating prisoner's dilemmas for capital allocation) and narrative-driven category creation.[4] The firm influences the ecosystem through public writings—e.g., on cryptography's return to crypto, DePIN's future, and biohacking—shaping founder strategies, investor theses, and protocol designs while backing 20-23% of investments in life sciences/healthcare and communications tech.[2][4][6]
Compound is poised to deepen its "sequencing vs. equal odds" strategy in deep tech, capitalizing on trends like perception markets, autonomous biology commercialization, and crypto primitives amid maturing AI and Web3 cycles.[4][6] Expect expanded research output and larger seed leads as deep tech exits accelerate, potentially evolving its influence toward ecosystem orchestration via theses on biosecurity and narrative receptacles. This positions Compound to not just fund futures, but actively sequence them—echoing its core mission of accelerating founder visions in an increasingly technical world.[4][5]
Key people at Compound VC.
